https://gmpq.org/etude-de-phase-iii-multicentrique-ouverte-a-repartition-aleatoire-et-en-deux-etapes-visant-a-comparer-lassociation-480vd-cc-92480-bortezomib-et-dexamethasone-et-lassociati/2025-07-13T10:08:16-04:00https://gmpq.org/a-phase-3-two-stage-randomized-multi-center-controlled-open-label-study-comparing-iberdomide-maintenance-to-lenalidomide-maintenance-therapy-after-autologous-stem-cell-transplantation-asct-in-p/2024-05-28T09:21:55-04:00https://gmpq.org/magnetismm-7-etude-de-phase-3-a-repartition-aleatoire-et-a-2-groupes-visant-a-evaluer-lelranatamab-pf-06863135-comparativement-au-lenalidomide-chez-des-patients-attein/2025-07-13T09:58:16-04:00https://gmpq.org/monumental-6-etude-de-phase-3-avec-repartition-aleatoire-comparant-le-talquetamab-en-association-avec-la-pomalidomide-tal-p-le-talquetamab-en-association-avec-le-teclistamab-tal-tec-et-une-assoc/2024-05-28T09:20:15-04:00https://gmpq.org/magnetismm-30-etude-ouverte-de-phase-1b-visant-a-evaluer-lelranatamab-en-association-avec-liberdomide-chez-des-participants-atteints-dun-myelome-multiple-en-rechute-ou-refra/2024-05-28T09:18:46-04:00https://gmpq.org/projet-de-recherche-de-phase-3-portant-sur-lassociation-du-teclistamab-au-lenalidomide-et-du-teclistamab-seul-par-rapport-au-lenalidomide-seul-chez-des-participants-atteints-dun-myelome-multiple-n/2024-09-24T13:37:49-04:00https://gmpq.org/premiere-etude-de-phase-1-ouverte-chez-lhomme-visant-a-evaluer-la-securite-lactivite-antitumorale-la-pharmacocinetique-et-la-pharmacodynamique-de-sar446523-un-anticorps-monoclonal-anti-gprc5d-a/2025-01-23T14:23:54-05:00https://gmpq.org/my-13-etude-sur-un-traitement-au-daratumumab-a-duree-fixe-par-rapport-a-un-traitement-continu-au-daratumumab-chez-les-adultes-ages-atteints-dun-myelome-multiple-nouvellement-diagnostique-q/2025-03-31T18:23:08-04:00https://gmpq.org/monumental-6-etude-de-phase-3-avec-repartition-aleatoire-comparant-le-talquetamab-en-association-avec-la-pomalidomide-tal-p-le-talquetamab-en-association-avec-le-teclistamab-tal-tec-et-une/2025-03-31T18:24:05-04:00https://gmpq.org/c1071030-magnestismm-30-etude-ouverte-de-phase-ib-visant-a-evaluer-lelranatamab-en-association-avec-liberdomide-chez-des-participants-atteints-dun-myelome-multip/2025-03-31T18:21:09-04:00https://gmpq.org/borealis-cmrg010-etude-ouverte-a-bras-unique-adaptee-a-la-reponse-portant-sur-liberdomide-le-bortezomib-hebdomadaire-et-la-dexamethasone-iberbd-avec-lisatuximab-ajoute-sur/2025-03-31T18:20:48-04:00https://gmpq.org/majestec-7-64007957mmy3005-etude-randomisee-de-phase-3-comparant-teclistamab-en-association-avec-daratumumab-sc-et-lenalidomide-tec-dr-et-talquetamab-en-association-avec-daratumumab-sc-et-lenalid/2025-07-13T09:32:54-04:00https://gmpq.org/im048022-etude-multicentrique-de-phase-3-a-repartition-aleatoire-a-groupe-temoin-sans-insu-et-a-deux-stades-visant-a-comparer-le-traitement-dentretien-par-liberdomide-au-traitem/2025-07-13T09:40:25-04:00https://gmpq.org/my13-etude-sur-un-traitement-au-daratumumab-a-duree-fixe-par-rapport-a-un-traitement-continu-au-daratumumab-chez-les-adultes-ages-atteints-dun-myelome-multiple-nouvellement-diagnostique-qui/2025-07-13T09:42:40-04:00https://gmpq.org/iraklia-etude-ouverte-de-phase-iii-a-repartition-aleatoire-evaluant-ladministration-sous-cutanee-par-rapport-a-ladministration-intraveineuse-disatuximab-en-assoc/2025-07-13T09:49:22-04:00https://gmpq.org/majestec-9-etude-de-phase-iii-a-repartition-aleatoire-comparant-le-teclistamab-en-monotherapie-a-lassociation-de-pomalidomide-de-bortezomib-et-de-dexamethasone-pvd-ou-a-l/2025-07-13T09:49:38-04:00https://gmpq.org/c1071006-ndmm-spring-summer-2023/2025-07-13T09:53:59-04:00https://gmpq.org/magnetismm-32-a-phase-3-open-label-study-of-elranatamab-monotherapy-versus-elotuzumab-pomalidomide-dexamethasone-epd-or-pomalidomide-bortezomib-dexamethasone-pvd-or-carfilzomib-dexamethaso/2025-07-13T10:02:14-04:00https://gmpq.org/bites-hmr-evaluation-de-la-reponse-aux-traitements-chez-les-patients-recevant-du-teclistamab-en-externe-administration-de-teclistamab-en-externe-dans-le-contexte-de-lunite-de-suivi/2025-07-13T10:13:19-04:00